Publications
Detailed Information
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Soo Jin | - |
dc.contributor.author | Kim, Jihye | - |
dc.contributor.author | Kim, Hee Seung | - |
dc.contributor.author | Lee, Jeong-Won | - |
dc.contributor.author | Chang, Ha Kyun | - |
dc.contributor.author | Lee, Keun Ho | - |
dc.contributor.author | Kim, Dae-Yeon | - |
dc.contributor.author | Kim, Sunghoon | - |
dc.contributor.author | Chang, Suk-Joon | - |
dc.contributor.author | Han, Seung Su | - |
dc.contributor.author | Park, Sang-Yoon | - |
dc.contributor.author | Shim, Seung-Hyuk | - |
dc.date.accessioned | 2022-04-12T04:15:28Z | - |
dc.date.available | 2022-04-12T04:15:28Z | - |
dc.date.created | 2020-05-15 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.citation | Journal of Gynecologic Oncology, Vol.31 No.2, p. e15 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177935 | - |
dc.description.abstract | Objective: To evaluate the effectiveness and safety of the combination of pegylated liposomal doxorubicin with carboplatin (CD) compared with those of carboplatin and paclitaxel (CP) for platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer in a real-world setting in Korea. Methods: We enrolled relevant patients from 9 institutions. All patients received CD or CP as the second- or third-line chemotherapy in routine clinical practice during 2013-2018. The primary endpoints were progression-free survival (PFS) and toxicity. The secondary endpoint included the objective response rate (ORR). Results: Overall, 432 patients (224 and 208 in the CD and CP groups, respectively) were included. With a median follow-up of 18.9 months, the median PFS was not different between the groups (12.7 vs. 13.6 months; hazard ratio, 1.161; 95% confidence interval, 0.923-1.460; p=0.202). The ORR was 74.6% and 80.1% in the CD and CP group, respectively (p=0.556). Age and surgery at relapse were independent prognostic factors. More patients in the CD group significantly experienced a grade 3 to 4 hematologic toxicity and hand-foot syndrome (13.8% vs. 6.3%), whereas grade 2 or more alopecia (6.2% vs. 36.1%), peripheral neuropathy (4.4% vs. 11.4%), and allergic/hypersensitivity reaction (0.4% vs. 8.5%) developed more often in the CP group. Conclusions: The safety and effectiveness of chemotherapy with CD in a real-world setting were consistent with the results from a randomized controlled study. The different toxicity profiles between the 2 chemotherapy (CD and CP) regimens should be considered in the clinical practice. | - |
dc.language | 영어 | - |
dc.publisher | 대한부인종양학회 | - |
dc.title | Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study | - |
dc.type | Article | - |
dc.identifier.doi | 10.3802/jgo.2020.31.e15 | - |
dc.citation.journaltitle | Journal of Gynecologic Oncology | - |
dc.identifier.wosid | 000517766900005 | - |
dc.identifier.scopusid | 2-s2.0-85085050504 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | e15 | - |
dc.citation.volume | 31 | - |
dc.identifier.kciid | ART002566020 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Hee Seung | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.